文章：

免疫疗法在胃食管癌中的作用——进展、挑战与未来策略

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies

原文发布日期：14 November 2023

DOI: 10.3390/cancers15225401

类型: Article

开放获取: 是

英文摘要：

Background: Gastroesophageal cancers (GECs) carry considerable morbidity and mortality, and demonstrate geographical histological variances in addition to molecular heterogeneity. Consequently, the immunogenicity of the different subtypes, which can predict the likelihood of immunotherapy response, can vary. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of many cancer types over the past decade but has been slower to gain a foothold in the treatment paradigm of GECs. Methods: This article reviews the existing evidence and use approvals for immunotherapies and immune-based treatments in GECs, in the neoadjuvant, adjuvant and metastatic disease settings. The challenges of and limitations to ICI application in current clinical practice are examined. Ongoing clinical trials and future directions of research are also considered. Conclusion: ICI therapy has become an established treatment option within GECs, both perioperatively and in advanced disease. However, nuances in terms of its use are not yet fully understood. Ongoing research proposes to broaden the application of immunotherapies in GECs with the potential to continue to improve outcomes.

摘要翻译： 

背景：胃食管癌具有较高的发病率和死亡率，除分子异质性外还存在地域性组织学差异。因此，不同亚型的免疫原性（可预测免疫治疗反应可能性）存在显著差异。过去十年间，免疫检查点抑制剂疗法已改变多种癌症的治疗格局，但在胃食管癌治疗领域的应用进展相对缓慢。 方法：本文系统综述了新辅助、辅助及转移性胃食管癌治疗中免疫疗法及免疫相关治疗的现有证据与应用批准，分析了当前临床实践中免疫检查点抑制剂应用面临的挑战与局限，并对正在进行的临床试验及未来研究方向进行探讨。 结论：免疫检查点抑制剂疗法已成为胃食管癌围手术期及晚期疾病的标准治疗选择，但其临床应用的具体策略尚未完全明确。持续深入的研究有望拓展免疫疗法在胃食管癌中的应用范围，并可能进一步提升临床疗效。

原文链接：

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies